利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.051 秒)

    PRLTS proteins and DNA's encoding the same
    71.
    发明授权
    PRLTS proteins and DNA's encoding the same 失效
    PRLTS蛋白和DNA的编码相同

    公开(公告)号：US5834245A

    公开(公告)日：1998-11-10

    申请号：US506864

    申请日：1995-07-25

    申请人： Yusuke Nakamura ,  Yoshiyuki Fujiwara

    发明人： Yusuke Nakamura ,  Yoshiyuki Fujiwara

    IPC分类号： A61K38/00 ,  C07K14/82 ,  C12N15/12 ,  C12N15/63

    CPC分类号： C07K14/82 ,  A61K38/00

    摘要： A gene is provided which is present in the deletion region of a chromosome common in lung cancer, hepatocellular carcinoma and colorectal cancer and encodes a novel protein, a protein encoded by the gene (PRLTS protein), and a method of discriminating tumor cells. With respect to the human chromosome 8, a detailed gene map was prepared, the chromosome of each of lung cancer, hepatocellular carcinoma and colorectal cancer tissues was analyzed, and a gene encoding a novel protein was cloned to thereby determine the structure thereof. A gene analysis was conducted with the use of a DNA probe derived from the above gene, and consequently mutations in the gene were confirmed in the lung cancer, hepatocellular carcinoma and colorectal cancer tissues.

    摘要翻译： 提供存在于肺癌，肝细胞癌和结肠直肠癌中常见的染色体的缺失区域中的基因，并编码新的蛋白质，由该基因编码的蛋白质（PRLTS蛋白质）和鉴别肿瘤细胞的方法。 对于人染色体8，制备了详细的基因图，分析了肺癌，肝细胞癌和结肠直肠癌组织的染色体，克隆了编码新蛋白的基因，从而确定了其结构。 使用源自上述基因的DNA探针进行基因分析，因此在肺癌，肝细胞癌和结肠直肠癌组织中证实了基因突变。

    Tumor suppressor gene
    73.
    发明授权
    Tumor suppressor gene 失效
    肿瘤抑制基因

    公开(公告)号：US5559023A

    公开(公告)日：1996-09-24

    申请号：US384850

    申请日：1995-02-07

    申请人： Yusuke Nakamura ,  Takashi Imai

    发明人： Yusuke Nakamura ,  Takashi Imai

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/82 ,  C12N5/10 ,  C07H21/04

    CPC分类号： C07K14/82 ,  C07K14/4703 ,  A61K38/00

    摘要： A detailed genetic map on human chromosome 11 was prepared. Then, a commonly deleted region on the chromosome in the tumor tissues of patients with multiple endocrine neoplasia type 1 was identified. Further, by linkage analysis of a family line with this disease, a genetic cause for this disease was localized. A gene present in the region common to these observations was cloned and the structure of this gene was determined. Because a protein coded by this DNA is homologous with those of transcriptional factors, it is expected that the above-mentioned gene may be a novel tumor suppressor gene. Further, it is also expected that the above-mentioned gene and a protein coded for thereby may be useful in preparation of a remedy for cancer and a diagnostic drug for cancer.

    摘要翻译： 准备了人类染色体11上的详细遗传图谱。 然后，鉴定了多发性内分泌瘤1型患者肿瘤组织染色体上普遍缺失的一个区域。 此外，通过家族系与这种疾病的联系分析，本病的遗传原因是本病。 克隆了与这些观察结果共同的区域中存在的基因，并测定了该基因的结构。 由于由该DNA编码的蛋白质与转录因子的蛋白质同源，所以预期上述基因可能是新的肿瘤抑制基因。 此外，还预期上述基因和由此编码的蛋白质可用于制备癌症治疗剂和癌症诊断药物。

    Modified MELK peptides and vaccines containing the same
    79.
    发明授权
    Modified MELK peptides and vaccines containing the same 有权
    改良的MELK肽和含有它们的疫苗

    公开(公告)号：US08871719B2

    公开(公告)日：2014-10-28

    申请号：US13574774

    申请日：2011-01-24

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/00 ,  A61K39/00 ,  C12N9/12 ,  A61K39/39

    CPC分类号： C12Y207/11025 ,  A61K39/0011 ,  A61K39/39 ,  C12N9/1205

    摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.

    摘要翻译： 由修饰的MELK表位肽或其免疫活性片段的氨基酸序列组成的分离肽，其结合HLA抗原并且具有比野生型MELK表位肽更高的细胞毒性T淋巴细胞（CTL）诱导性，因此适用于 本文描述了癌症免疫治疗或子宫内膜异位症免疫治疗的背景，更特别的是癌症或子宫内膜异位症疫苗。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 进一步提供了编码这些上述肽中的任何一种的核酸以及包含上述肽或核酸中任何一种的药物物质和组合物。 本发明的肽，核酸，药物和组合物在癌症，肿瘤和子宫内膜异位症的治疗中具有特别的用途。

    Genes and polypeptides relating to breast cancers
    80.
    发明授权
    Genes and polypeptides relating to breast cancers 有权
    与乳腺癌相关的基因和多肽

    公开(公告)号：US08673548B2

    公开(公告)日：2014-03-18

    申请号：US12377024

    申请日：2007-08-10

    申请人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

    IPC分类号： C12Q1/00 ,  C07K14/00

    CPC分类号： C07K16/18 ,  A61K31/7088 ,  C07K14/47 ,  C07K14/4748 ,  C12N2310/14 ,  C12Q1/485 ,  G01N33/5011 ,  G01N33/5035 ,  G01N33/57415 ,  G01N2333/9121 ,  G01N2510/00

    摘要： The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.

    摘要翻译： 本申请提供了新的人类基因A7322，其表达在乳腺癌中显着升高。 本申请还提供了人类基因F3374，其在乳腺癌中的表达显着升高。 由此编码的这些基因和多肽可用于例如乳腺癌的诊断，以及用于开发针对乳腺癌的药物的靶分子。 本发明的特征在于筛选PBK / TOPK的激酶活性的调节剂的方法。 本发明还提供筛选用于预防或治疗癌症（例如乳腺癌）的药剂的方法。